Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | CDC25A | P30304 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | PLK1 | P53350 | 3/20 | 0.41 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2004427 | 0.90 | PLA2G2A (0.62) | AKR1B1PLA2G2AALDH1A1LMNASLC22A12 | |
| SCHEMBL2004339 | 0.88 | SLC22A12 (0.53) | AKR1B1PLA2G2AALDH1A1LMNASLC22A12 | |
| SCHEMBL2008137 | 0.87 | PLA2G2A (0.65) | PLA2G2AALDH1A1LMNASLC22A12PPARG | |
| SCHEMBL2002884 | 0.83 | PLA2G2A (0.56) | AKR1B1PLA2G2AALDH1A1LMNASLC22A12 | |
| SCHEMBL2003929 | 0.82 | LMNA (0.61) | PLA2G2AALDH1A1LMNASLC22A12PPARG | |
| SCHEMBL2010075 | 0.80 | AKR1B1 (0.49) | AKR1B1PLA2G2AALDH1A1LMNASLC22A12 | |
| SCHEMBL2001314 | 0.77 | AKR1B1 (0.56) | AKR1B1PLA2G2AALDH1A1LMNASLC22A12 | |
| SCHEMBL2008295 | 0.77 | AKR1B1 (0.56) | AKR1B1ALDH1A1LMNACDC25AMCL1 | |
| SCHEMBL2003634 | 0.77 | PLA2G2A (0.46) | AKR1B1PLA2G2AALDH1A1CAMK2A | |
| SCHEMBL2004159 | 0.76 | PLA2G2A (0.81) | PLA2G2AALDH1A1LMNAPPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | IRONWOOD PHARMACEUTICALS, INC. | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | AKR1B1 1157/4885PLA2G2A 3285/4885ALDH1A1 1229/4885 |
| US-20090264653-A1 | USEFUL INDOLE COMPOUNDS | FAAH, FAAH2, AANAT | AKR1B1 696/4885PLA2G2A 326/4885ALDH1A1 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.